Advertisement
Document › Details
G1 Therapeutics, Inc.. (5/16/17). "Press Release: G1 Therapeutics Announces Pricing of Initial Public Offering". Research Triangle Park, NC.
Region | United States (USA) | |
Organisation | G1 Therapeutics Inc. (Nasdaq: GTHX) | |
Organisation 2 | Wedbush PacGrow | |
Group | Wedbush (Group) | |
Product | small-molecule cancer drug | |
Product 2 | investment banking | |
Index term | G1 Therapeutics–SEVERAL: investment, 201705 IPO $105m+$11.7m net $108.6m with 7m+782k shares common stock at $15/share | |
Person | Uhl, Robert H. (Westwicke Partners 201806 Managing Director) | |
Person 2 | Bagby, Laura (6 Degress Communications 201701) | |
G1 Therapeutics, Inc., a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of its common stock at the initial public offering price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on May 17, 2017 under the ticker symbol “GTHX.”
J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Needham & Company, LLC and Wedbush Securities Inc. are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on May 16, 2017. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806 or by faxing (631) 254-7140.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is based in Research Triangle Park, NC.
Contacts
Investors:
Robert Uhl
Westwicke Partners
858-356-5932
robert.uhl@westwicke.com
Media:
Laura Bagby
6 Degrees Communications
312-448-8098
lbagby@6degreespr.com
Record changed: 2023-06-05 |
Advertisement
More documents for G1 Therapeutics Inc. (Nasdaq: GTHX)
- [1] G1 Therapeutics, Inc.. (11/22/22). "Press Release: G1 Therapeutics Announces Closing of Offering of Common Stock". Research Triangle Park, NC....
- [2] G1 Therapeutics, Inc.. (9/21/18). "Press Release: G1 Therapeutics Announces Closing of Offering of Common Stock". Research Triangle Park, NC....
- [3] G1 Therapeutics, Inc.. (9/18/18). "Press Release: G1 Therapeutics Announces Pricing of Offering of Common Stock". Research Triangle Park, NC....
- [4] G1 Therapeutics, Inc.. (9/17/18). "Press Release: G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq in Small Cell Lung Cancer in Fourth Quarter 2018". Research Triangle Park, NC....
- [5] G1 Therapeutics, Inc.. (9/17/18). "Press Release: G1 Therapeutics Announces Proposed Offering of Common Stock". Research Triangle Park, NC....
- [6] G1 Therapeutics, Inc.. (9/13/18). "Press Release: G1 Therapeutics Announces Appointment of Garry Nicholson to Board of Directors". Research Triangle Park, NC....
- [7] G1 Therapeutics, Inc.. (7/9/18). "Press Release: G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel". Research Triangle Park, NC....
- [8] G1 Therapeutics, Inc.. (3/12/18). "Press Release: G1 Therapeutics Announces Closing of Offering of Common Stock". Research Triangle Park, NC....
- [9] G1 Therapeutics, Inc.. (3/7/18). "Press Release: G1 Therapeutics Announces Pricing of Offering of Common Stock". Research Triangle Park, NC....
- [10] G1 Therapeutics, Inc.. (3/5/18). "Press Release: G1 Therapeutics Announces Proposed Offering of Common Stock". Research Triangle Park, NC....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top